

The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission

Antoine Chaillon, Thierry Wack, Martine Braibant, Laurent Mandelbrot, Stéphanie Blanche, Josiane Warszawski, Francis Barin

► **To cite this version:**

Antoine Chaillon, Thierry Wack, Martine Braibant, Laurent Mandelbrot, Stéphanie Blanche, et al.. The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission. *Retrovirology*, BioMed Central, 2012, 9 (Suppl 2), pp.P44. inserm-00731778


HAL Id: inserm-00731778

<https://www.hal.inserm.fr/inserm-00731778>

Submitted on 13 Sep 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



POSTER PRESENTATION

Open Access

The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission

A Chaillon^{1*}, T Wack², M Braibant¹, L Mandelbrot³, S Blanche⁴, J Warszawski⁵, F Barin¹

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

Background

It has been hypothesized that neutralizing antibodies (nAbs) should have broad specificity to be effective in protection against diverse HIV-1 variants. The mother-to-child transmission of HIV-1 is a model that provides the opportunity to examine whether the breadth of maternal nAbs would be associated with protection of infants from infection.

Methods

Samples were obtained at delivery from 57 transmitting mothers (T) matched with 57 non-transmitting mothers (NT) enrolled in the multicenter French Perinatal Cohort (ANRS EPF CO1) between 1990 and 1996. The mothers did not receive antiretroviral therapy during pregnancy, and did not breastfeed their infants. Sixty-eight (59.6%) and 46 (40.4%) women were infected by B and non-B viruses, respectively. Neutralization assays were carried out in TZM-bl cells using a panel of 10 primary isolates of 6 clades (A, B, C, F, CRF01_AE, CRF02_AG) selected for their moderate (tier 2) or low (tier 3) sensitivity to neutralization. The presence and titers of Nab to each strain, and the breadth of maternal nAbs at delivery were compared between T and NT mothers.

Results

Although there was a trend for both higher frequency and higher titers of nAbs in NT mothers vs T mothers for almost all the primary isolates that were tested, the differences were not statistically different when considering the entire population. However a few statistically significant differences were observed with higher frequency

or higher titers of nAbs toward several individual strains in NT mothers when analyzing separately the B-infected or non-B infected mothers.

Conclusion

Our study confirms that the breadth of maternal nAbs is not associated with protection of infants from infection. However it suggests that, depending of the population, some primary isolates could be indicators of nAbs associated with a lower risk of MTCT.

Author details

¹INSERM U966 Research Unit, F. Rabelais University, Tours, France. ²INSERM U1018, Le Kremlin-Bicêtre, Paris, France. ³Louis Mourier Hospital, Paris-Diderot University, Paris, France. ⁴Necker Hospital, EA 3620, Paris-Descartes University, Paris, France. ⁵Inserm U1018, Le Kremlin-Bicêtre, Paris, France.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P44

Cite this article as: Chaillon *et al.*: The breadth of maternal HIV-1 specific neutralizing antibodies is not associated with a lower risk of mother-to-infant transmission. *Retrovirology* 2012 **9**(Suppl 2):P44.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹INSERM U966 Research Unit, F. Rabelais University, Tours, France
Full list of author information is available at the end of the article